價(jià)格 | ¥196 | ¥453 | ¥659 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 Fatostatin | 英文名稱:Fatostatin hydrobromide |
CAS:298197-04-3 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.91% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T6832 |
名稱 | Fatostatin hydrobromide |
描述 | Fatostatin hydrobromide (Fatostatin A HBr) ia an inhibitor of sterol regulatory element binding protein (SREBP). It impairs the activation of SREBP-1 and SREBP-2. |
細(xì)胞實(shí)驗(yàn) | Cell lines: CHO-K1 cells. Concentrations: 20 μM. Incubation Time: 20 h. Method: On day 0,CHO-K1 cells are plated out onto a 96-well plate in medium A.On day 2,the cells are transiently cotransfected with pCMV-PLAP-BP2(513–1141),pCMV-SCAP,and pAc-β-gal,using Lipofectamine reagent.After incubation for 5 hr,the cells are washed with PBS and then incubated in medium B,in the absence or presence of fatostatin (20 μM) or sterols (10 μg/mL cholesterol and 1 μg/mL 25-hydroxycholesterol).After 20 hr of incubation,an aliquot of the medium is assayed for secreted alkaline phosphatase activity.The cells in each well are lysed and used for measurement of β-galactosidase activities.The alkaline phosphatase activity is normalized by the activity of β-galactosidase. |
動(dòng)物實(shí)驗(yàn) | Animal Models: Obese (ob/ob) mice (C57BL/6J background). Formulation: 10% DMSO in PBS. Dosages: 30 mg/kg. Administration: intraperitoneal injection |
體外活性 | Fatostatin inhibits the insulin-induced adipogenesis of 3T3-L1 cells and the serum-independent growth of human androgen-independent prostate cancer (DU145) cells. Fatostatin suppresses cell proliferation and anchorage-independent colony formation in both androgen-responsive LNCaP and androgen-insensitive C4-2B prostate cancer cells. Fatostatin blocks the activation of SREBPs in cells in tissue culture.Fatostatin also reduced in vitro invasion and migration in both cell lines. Further, fatostatin causes G2/M cell cycle arrest and induces apoptosis by increasing caspase-3/7 activity and the cleavages of caspase-3 and PARP. |
體內(nèi)活性 | Fatostatin significantly inhibits subcutaneous C4-2B tumor growth and markedly decreases serum PSA level compared to the control group. Fatostatin blocks increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake. |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 3.75 mg/mL (10 mM), Sonication is recommended. Ethanol : 58 mg/mL (154.53 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
關(guān)鍵字 | Golgi | ob/ob | inhibit | Fatostatin hydrobromide | prostate | SREBP-mediated | cancer | mice | insulin-induced | adipogenesis | Fatostatin Hydrobromide | Fatty Acid Synthase (FASN) | gene | human | expression | Inhibitor | 125B11 |
相關(guān)產(chǎn)品 | A-769662 | Lycorine | Orlistat | trans-Chalcone | Ezetimibe | Denifanstat | TVB-3664 | FASN-IN-1 | Pyrazinamide | L-Carnitine | VY-3-135 | Trimetazidine dihydrochloride |
相關(guān)庫(kù) | 抑制劑庫(kù) | 脂代謝化合物庫(kù) | 抗癌活性化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 抗癌化合物庫(kù) | 已知活性化合物庫(kù) | NO PAINS 化合物庫(kù) | 離子通道庫(kù) | 抗肥胖化合物庫(kù) | 膜蛋白靶向化合物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2024-12-26 | |
詢價(jià) |
VIP7年
|
臺(tái)州市科瑞生物技術(shù)有限公司
|
2024-12-11 | |
¥220.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
詢價(jià) |
VIP4年
|
陜西締都醫(yī)藥化工有限公司
|
2024-11-13 |